GSK Pharma to invest Rs 1,000 crore at its Bengaluru facility

The facility will be operational by 2017

GlaxoSmithKline Pharmaceuticals’ (GSK India) greenfield manufacturing facility at Bengaluru, having an installed capacity of over nine billion tablets and capsules per year, will be operational by 2017, according to a report in PTI.

The company said that it has decided to create a new greenfield manufacturing site at Vemgal near Bengaluru, to be operational by 2017. Initially, the site will supply a range of solid dose form products. The unit will have an installed annual capacity of over nine billion tablets and capsules to supply in the local market.
The new site, which represents up to Rs 1,000 crore in investments, will be the first greenfield pharma site GSK has built across the globe over the past 10 years. The state-of-the-art site will be the first factory designed for the new GSK production systems.

GSK India is also upgrading the Nashik site by investing in infrastructure across all areas with special focus on good manufacturing practices (GMP), safety and sustainability.

The company’s Nashik facility has completed enhancement of the existing Eltroxin facility in safety standards. The unit is ready to launch new products in Bactroban creams early next year.

BengaluruGlaxoSmithKline PharmaceuticalsGMPgreenfield